What's Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics.
Bioconjug Chem
; 33(11): 1996-2007, 2022 Nov 16.
Article
in English
| MEDLINE | ID: covidwho-1773911
ABSTRACT
Recent success of mRNA-based COVID-19 vaccines have bolstered the strength of nucleic acids as a therapeutic platform. The number of new clinical trial candidates is skyrocketing with the potential to address many unmet clinical needs. Despite advancements in other aspects, the systemic delivery of nucleic acids to target sites remains a major challenge. Thus, nucleic acid based therapy has yet to reach its full potential. In this review, we shed light on a select few prospective technologies that exhibit substantial potential over traditional nanocarrier designs for nucleic acid delivery. We critically analyze these systems with specific attention to the possibilities for clinical translation.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Nucleic Acids
/
Nanoparticles
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Bioconjug Chem
Journal subject:
Biochemistry
Year:
2022
Document Type:
Article
Affiliation country:
Acs.bioconjchem.2c00058
Similar
MEDLINE
...
LILACS
LIS